000 01488 a2200421 4500
005 20250513212255.0
264 0 _c20000824
008 200008s 0 0 eng d
022 _a0021-9738
024 7 _a10.1172/JCI9177
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLode, H N
245 0 0 _aMelanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction.
_h[electronic resource]
260 _bThe Journal of clinical investigation
_cJun 2000
300 _a1623-30 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
650 0 4 _aAnimals
650 0 4 _aAntigen-Presenting Cells
_xphysiology
650 0 4 _aCD4-Positive T-Lymphocytes
_ximmunology
650 0 4 _aCD40 Antigens
_xgenetics
650 0 4 _aCD40 Ligand
650 0 4 _aFemale
650 0 4 _aInterleukin-2
_xtherapeutic use
650 0 4 _aLymphocyte Activation
650 0 4 _aMelanoma, Experimental
_ximmunology
650 0 4 _aMembrane Glycoproteins
_xgenetics
650 0 4 _aMice
650 0 4 _aMice, Inbred C57BL
650 0 4 _aMice, Knockout
700 1 _aXiang, R
700 1 _aPertl, U
700 1 _aFörster, E
700 1 _aSchoenberger, S P
700 1 _aGillies, S D
700 1 _aReisfeld, R A
773 0 _tThe Journal of clinical investigation
_gvol. 105
_gno. 11
_gp. 1623-30
856 4 0 _uhttps://doi.org/10.1172/JCI9177
_zAvailable from publisher's website
999 _c10792884
_d10792884